What question did this study set out to answer?

To synthesize molecular mechanisms linking intestinal microbiome dysbiosis to nonalcoholic fatty liver disease pathogenesis and evaluate emerging gut-liver axis therapies.

December 16, 2019Journal of GastroenterologyOpen Access

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

View Full Paper

Ask AI

Bookmark

To synthesize molecular mechanisms linking intestinal microbiome dysbiosis to nonalcoholic fatty liver disease pathogenesis and evaluate emerging gut-liver axis therapies.
Reviewed the composition of intestinal microbes, encompassing bacteria, archaea, viruses, and fungi, and their crosstalk in human liver diseases.
Analyzed mechanisms of gut barrier impairment, intestinal permeability, and hepatic exposure to lipogenic and fibrotic substances.
Summarized pharmacological and microbial therapeutics targeting the gut-liver axis, including probiotics, synbiotics, farnesoid X receptor agonists, and fecal microbiota transplantation.
Intestinal microbiome imbalance compromises the intestinal barrier, facilitating microbial translocation and harmful substance delivery to the liver.
Elevated hepatic exposure to microbial products directly drives hepatic lipogenesis, chronic inflammation, and progressive liver fibrosis.
Targeting the gut-liver axis using fecal microbiota transplantation, farnesoid X receptor agonists, and microbiome-modulating agents shows therapeutic potential for reversing metabolic liver damage.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review highlights gut microbiome disruptions in nonalcoholic fatty liver disease, suggesting targeted therapies like microbiota transplantation can improve metabolic liver health.

Cite This Study

Hu et al. (2019) studied this question.

synapsesocial.com/papers/6a96c39e805b2d6b5dbb6fb6 https://doi.org/10.1007/s00535-019-01649-8

View Full Paper

Ask AI

Bookmark

Implication

Review highlights gut microbiome disruptions in nonalcoholic fatty liver disease, suggesting targeted therapies like microbiota transplantation can improve metabolic liver health.

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Key Points

Discussion

Implication

Cite This Study

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider